2956183-81-4
2956183-81-4
Chemical Structure
Gardiquimod hydrochloride
- CAS No.: 2956183-81-4
- Formula:C17H24ClN5O
- Molecular Weight:349.86
InChIKey: YHVYOGAFUOQBOL-UHFFFAOYSA-N
SMILES: OC(C)(CN1C(CNCC)=NC2=C1C3=C(C=CC=C3)N=C2N)C.Cl
Biological Activity: Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gardiquimod hydrochloride | Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18. [Content Brief]
- [2]. Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306. [Content Brief]
